Aim: Ischemic postconditioning is considered as a potent method to combat ischemic reperfusion injury than preconditioning and rapid initiation of reperfusion with potent antioxidant compounds can be one of the most effective treatments to reduce the infarct size and behavioral deficits as a result of ischemic insult. The present study aims to determine the postconditioning effects of metformin in experimental ischemia.
| INTRODUCTION
Cardiovascular diseases account for most noncommunicable dis- is previously reported to offer mild to moderate cardioprotection but exhibits limitations such as rapid utilization and clearance which results in 6, 7 limited activity.
Postischemic conditioning is accepted as a more effective means of cardioprotection over preconditioning owing to many factors. 8, 9 The major drawbacks of ischemic preconditioning include overproduction of reactive oxygen species and overloading of calcium in early stages, along with the unpredictability of ischemic events. [10] [11] [12] In this aspect, endogenous postconditioning can be more beneficial and can overrule the possible drawbacks of preconditioning.
The success rate and significance of ischemic reperfusion are highly influenced by two morphologically distinct cellular pathways, apoptosis, and necrosis. Both apoptosis and necrosis can highly contribute to the infarct size and can decide the success rate of postischemic functional recovery. 13, 14 The clinical significance of apoptosis of cardiomyocytes relies on the fact that inhibition/prevention of myocyte apoptosis can effectively prevent the loss of contractile cells and can thereby provide a multimodal therapeutic approach in cardiovascular diseases. 15, 16 Apoptosis and necrosis contribute equally for the progression of ischemic injury 17, 18 and preventing both these cellular events can afford protection in reperfusion injury. The significance of metformin as a potent antioxidant in protecting apoptosis/necrosis is previously described by the same authors 19, 20 contributing the role of nuclearrelated factor 2 (Nrf2 
| METHODS

| Cell culture
H9C2, rat cardiomyoblast cells procured from NCCS, Pune, India, was used for the present study. The cells were grown in Dulbecco's modified eagles medium (Sigma-Aldrich, St. Louis, MO, USA) supplemented with 10% fetal bovine serum (Gibco, Invitrogen, Grand Island, NY, USA) antibiotic solution containing penicillin (100 U/mL), streptomycin (100 μg/mL), and amphotericin B (2.5 μg/mL) and maintained at 5% CO 2 , 37°C in a humidified condition. 
| Cell viability assays
| Lactate dehydrogenase (LDH) assay
Lactate dehydrogenase leakage assay was performed as per the methods of Jurisic, 2003 . 24 The cell-free supernatant was mixed with 2.7 mL of potassium phosphate buffer, 6 mmol/L NADH, 30 mmol/L sodium pyruvate followed by 100 μL of cell-free supernatant. The change in optical density was measured at 340 nm, and the activity was determined using the equation.
| Live/dead fluorescent staining
The protective effect of metformin on ischemic perfusion-induced Enzyme activity (U∕mL) = ΔOD (OD at 0 minute − OD at 5 minutes)
| DNA fragmentation analysis
DNA fragmentation is the hall mark of apoptotic cells and ability of metformin to prevent apoptosis and subsequent DNA fragmentation in ischemic cells was analyzed in isolated genomic DNA. An untreated ischemic control was also maintained. Briefly cells after treatment and incubation were washed with PBS and subjected to genomic DNA isolation using DNA isolation kit (PureLink Genomic DNA isolation kit, Invitrogen) as per manufacturer's instruction. The isolated DNA was run on 1.5% agarose and was viewed in a gel documentation system (E-Gel Imager-Life Technologies, Maale HaHamisha, Israel).
| Comet assay
Alkaline gel electrophoresis was used to measure the extent of DNA damage in H9C2 cells after treatment with ischemic buffer. 
| Estimation of intracellular oxidative markers
Protein carbonyls and nitrate levels were measured in lysates prepared from 24-hour-treated cells as per procedures described early. Cellular carbonyl content was determined by the colorimetric method of Levine et al., 27 0.5 mL cell lysate was mixed with equal volumes of 10 mmol/L 2,4-dinitrophenylhydrazine in 2 mol/L HCl, incubated for 1 hour at room temperature with intermittent vortexing and mixed with 0.5 mL of 20% Trichloroacetic acid, followed by centrifugation at 11 000 g. The supernatant was discarded and the pellets were washed three times with 1 mL of ethyl acetate-ethanol mixture (1:1) and precipitated protein was redissolved in 0.6 mL of 6 mol/L guanidine solution. Carbonyl content was calculated from maximum absorbance (390 nm) using molar absorption coefficient of
The nitrite levels were estimated in cell lysates by the method of Lepoivre. 28 To 0.5 mL of cell lysate, 0.1 mL of sulfosalicylic acid was added and vortexed for 30 minutes. The samples were then centrifuged at 20 000 g for 15 minutes. The protein-free supernatant was used for the estimation of nitrite levels. To 200 μL of the supernatant, 30 μL of 10% NaOH was added, followed by 300 μL of Tris-HCl buffer and mixed well. To this, 530 μL of Griess reagent was added and incubated in the dark for 10-15 minutes, and the T A B L E 1 Primers used for the study mRNA Sequence absorbance was read at 540 nm against a Griess reagent blank.
Sodium nitrite solution was used as the standard. The amount of nitrite present in the samples was estimated from the standard curves obtained.
| Scratch wound-healing assay
In vitro wound-healing was assayed on ischemic-injured confluent H9C2 cells. The scratch wounds were made in cells exposed to ischemic buffer by a sterile 100 μL pipette tip through a premarked line. The cells were further washed with PBS to remove the nonadherent cells and grown in DMEM containing 2.5 μg/mL metformin for 24 hours. The closure of wound areas was captured using a phase contrast microscope at 10× magnification, and image was analyzed using MRI ImageJ analysis software (Wayne Rasband, NIH, Bethesda, MD, USA).
| mRNA analysis of apoptotic markers in H9C2 cells
Total RNA from treated groups as described previously was extracted using the TRizol method as per manufacturer's instruction (Invitrogen). Purified RNA was subjected to reverse transcription and amplification using Verso one-step RT-PCR kit (Thermoscientific India Pvt Ltd, Mumbai, India). PCR primers were supplied from Eurofins, India (Table 1 ). The PCR products were run on a 1.5% agarose gel containing 5 μg/mL ethidium bromide. Band intensity was normalized to values for GAPDH which was used as an internal control.
| Statistical significance
Unless indicated in the legends of figures, the reported values represent the means of triplicate from one representative experiment repeated three times±SD, and statistical significance was determined by One-way ANOVA using GraphPad prism statistical software Version 5.0, and metformin-treated ischemic group was compared with ischemic group and P-value of .01 was considered significant.
| RESULTS
| Cell viability assays
Sulforhodamine assay confirmed protective effects of metformin on postischemic injury. 2.5 μg/mL effectively increased the cell viability to 79.38% which can be considered significant. 28 Cell morphological characteristics were also improved with metformin treatment (Figure 1 ). The increased protein synthesis can be accounted as the protection over ischemic injury. LDH leakage is enhanced in cells undergoing ischemic injury, 29 and the results clearly shows significant decrease in LDH leakage which can be correlated with protective effects of metformin treatment followed by ischemic injury. 
| Metformin protects nuclear damages in ischemic-injured cells
| Annexin V staining for determination of apoptosis
A more quantitative data analysis of apoptosis was considered signifi- 
| DNA fragmentation analysis
DNA fragmentation was evident in ischemic-injured cells but 
| Comet assay
Comet assay confirmed considerable strand breaks and comet tails in cells after ischemic reperfusion. The increased strand breaks due to increased oxidative damage results in comet which is in accordance with findings of researchers like Dong et al. 31 Comet assay was used in the study particularly to monitor the genoprotective effects of metformin postconditioning ( Figure 5A ) and the pictures depict considerable reduction in tail length and decreased comet formation in metformin-treated cells ( Figure 5B ).
| Estimation of intracellular oxidative markers
Nitrate levels and protein carbonyl was measured in ischemic and formed early and hold more stability of carbonylated proteins. 32 The results confirmed nearly 63% increase in protein carbonylation after IRI which was reduced to 27% by metformin treatment ( Figure 6A ).
The treatment of metformin reduced the severe oxidative damage by inhibiting formation of irreversible carbonylated proteins and subsequent proteasomal degradations. 33 Nitrate levels followed a significant decrease after ischemic injury which is in accordance with findings of different researchers. 34, 35 Low concentrations of metformin effectively maintained the pool of intracellular nitrates which can lead to more NO ( Figure 6B ) and subsequent cytoprotection which is similar to simvastatin. 
| In vitro migration and wound-healing effects of metformin
The efficiency of metformin to enhance the cellular migration and retrieval of cells postischemic injury was measured by invasion and scratch assays. The wound area was reduced in group conditioned with metformin after ischemic injury ( Figure 7 ). Ischemic buffer-treated cells failed to close the wound after 48 hours of incubation which can be due to inefficiency of apoptotic cells to migrate whereas 2.5 μg/mL metformin-treated cells shown a wound closure and migration in a similar manner as that of untreated control cells.
| mRNA analysis of apoptotic markers in H9C2 cells
PCR analysis showed a significant decrease in expression of p21 and Bcl-2, Bcl-xL, the major antiapoptotic proteins following ischemic injury, whereas a considerable increase in FASL expression was observed. Addition of metformin exhibited increase in p21 and Bcl-xL and up to an extent Bcl-2 expression. FASL was found to be reduced significantly in metformin-treated H9C2 cells following ischemic injury.
The synchronization of antiapoptotic and apoptotic events is of critical significance in cellular homeostasis and the results clearly depicts a distinct protective effect of metformin via downregulating the FasL and upregulating p21 and Bcl-xL in a significant manner ( Figure 8A,B) 
| DISCUSSION
The unpredicted occurrence of ischemia reduces the chances of preconditioning which is the major limitation resulting in increased infarct size and reperfusion injury. Metformin apart from its antidiabetic effects is proved to be effective as an antioxidant 37 and cardioprotective agent. 38 The same authors have reported the antiapoptotic effects of metformin in acetaminophen-challenged human hepatocytes 19 mainly due to the antioxidant potential of metformin.
Similarly, the antioxidant activity of metformin can aid in limiting The significance of postconditioning as a more viable therapeutic approach is already reviewed, and the present study discusses the possibility of established drug metformin to reverse the induction of apoptosis in ischemic conditions. The prime concern while using a hypoglycemic drug for other therapeutic applications is risk of hypoglycemia, but it is already established that metformin being a noninsulin secretagogues will not induce hypoglycemia 39, 40 and above all the dosages used for the present study are 2.5 μg/mL which is well below the normal usage levels.
The viability studies after metformin treatment in ischemiareperfused cells especially, SRB assay clearly depicted the enhancement in cell viability with nearly 40% increase in total viability.
Decrease in membrane damage was also proved by LDH leakage assay. These results confirmed increased protection at lower concentration of metformin (2.5 μg/mL) than higher concentrations. reported previously by Zhang et al., 41 and Zhao et al., 9 via different phytochemicals, but in our study, the concentration of metformin is comparatively lesser and there are no significant side effects of metformin at these concentrations.
Metformin was found to influence the intracellular pool of nitrate which is quite relevant in the context that nitrate has marked protective effects in ischemia-reperfusion injury of both heart and kidney. 34 The increase in nitrate levels can in turn serve as nitrite pool in heart by providing NOS-independent NO production. The rate of oxidative damage followed by ischemic cell injury was correlated with protein carbonyl levels. As per the findings, it can be observed that metformin administration resulted in a significant decrease in protein carbonyl level confirming decrease in intracellular oxidative damages.
The extent of DNA break in ischemia is previously reported by workers like Dong et al., 31 but a more quantitative assessment like comet assay had given precise inferences regarding DNA damages. Our results confirm incidence of DNA strand breaks and increased nuclear damage in cells exposed to ischemia. Comet assay employed by us gave better assessment of the extent of DNA damages in H9C2 cells postmetformin treatment. The radical scavenging potential of metformin should have reduced the generation and persistence of free radicals especially hydroxyl radicals which in turn decreased the nuclear damage.
Ischemia reperfusion eventually damages enough to cause a wound, and the role of ROS in these events is quite well established. Bcl-2 and survivin. 46 We also report similar mechanism for protective effect of metformin against ischemic apoptosis and cell death. The enhancement of Bcl-xL expression by AMPK in thymocytes is reported by Cao et al., 47 and Liu et al., 48 but the same in cardiomyocytes is being reported for the first time. Exposure of cardiomyocytes to hypoxia enhances FasL expression and apoptosis; 49, 50 here also metformin produced a significant decrease in expression which resulted in prevention of apoptosis.
| CONCLUSION
Cardiac injury and cell death by apoptosis following ischemic reperfusion injury is the major cause of morbidity and mortality. Our results
shows the significance of metformin as a postischemic conditioning agent to reduce the apoptotic events and envisage the role of Bcl-2 signaling pathways in affording cardioprotection which can aid in developing new therapeutic approaches against ischemic reperfusion injury. 
